Infectious agents and environmental factors in lymphoid malignancies

Blood Reviews

Volumn 10, Issue 2, 1996, Pages 89-94

  Toren, A ^a,b   Ben Bassat, I ^a,b   Rechavi, G ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL PARASITOSIS; ANTIBIOTIC THERAPY; APOPTOSIS; AVIAN LEUKOSIS ONCOVIRUS; B CELL LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER SUSCEPTIBILITY; CELL CYCLE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; HELICOBACTER PYLORI; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; LYMPHOPROLIFERATIVE DISEASE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOCIAL STATUS; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; VIRUS INFECTION;

EID: 0030017651     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90037-5     Document Type: Article

References (63)

1. Ramot B, Magrath I. Hypothesis: the environment is a major determinant of the immunological sub type of lymphoma and acute lymphoblastic leukemia in children (annotation). Br J Haematol 1982; 52: 183-189.
2. Ramot B. Environment and malignancies of the lymphatic system. In: Miller R Unusual Occurrences as Clues to Cancer Etiology. London: Taylor and Francis, 1988: 87-94.
3. Breslow NE, Langholz B. Childhood cancer incidence: geographical and temporal variations. Int J Cancer 1983; 32: 703-716.
4. Klein G. Lymphoma development in mice and human: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Sci USA 1979; 76: 2446.
5. Klein G, Klein E. Evaluation of tumors and the impact of molecular oncology. Nature 1985; 315: 190-195.
6. Magrath I. Clinical and pathological features of Burkitt's lymphoma and their resistance to treatment. In: Levine PH, eds. Epstein-Barr Virus and Associated Diseases. Boston, MA: Martinus Nijhoff, 1986: 631-647.
7. Erikson J, Nishikura K, ar-Rushdi A. Translocation of and immunoglobulin kappa locus to a region 3' of an unrearranged c-myc oncogene enhances c-myc transcription. PNAS 1983; 80: 7581-7585.
8. Nishikura K, ar-Rushdi A, Erikson J, Dejesus E, Dugan D, Croce CM. Repression of rearranged μu gene and translocated c-myc in mouse 3T3 cells × Burkitt lymphoma cell hybrids. Science 1984; 224: 399-402.
9. Hayward WS, Neel BG, Astrin SM. Activation of cellular oncogene by promotor insertion in ALV-induced lymphoid leukosis. Nature 1981; 290: 475-480.
10. Herdiner BG, Chiramizu BT, Jewett NE et al. Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type-1associated T-cell transformation. Blood 1992; 79:1768-1775.
11. Shiramizu B, Herndier BG, McGrath MS. Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphoma. Cancer Res 1994; 54: 2069-2072.
12. Rechavi G, Ben-Bassat I, Berkowicz M et al. Molecular analysis of Burkitt's leukemia in two hemophilic brothers with AIDS. Blood 1987; 70: 1713-1717.
13. Subar M, Neri A, Inghirami G et al. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 1988; 72: 667-674.
14. Ballerini P, Gaidano G, Gong JZ et al. Multiple genetic lesions in acuired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993; 81: 166-172.
15. Amariglio N, Vonsover A, Hakim I et al. Immunoglobulin VH3-positive AIDS-related lymphoma: a possible role for the HIV gp120 superantigen. Acta Hematologica 1994; 91: 103-105.
16. Beral V, Peterman T, Berkelman R et al. AIDS-associated non-Hodgkin's lymphoma. Lancet 1991; 337: 805-809.
17. Shibata D, Weiss LM, Hernandez AM et al. Bpstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with human immunodeficiency virus. Blood 1993; 81: 2102-2106.
18. Knowls DM, Inghirami G, Ubriaco A et al. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic of the Epstein-Barr virus. Blood 1989; 73: 792-797.
19. Shimizu B, Herndier B, Meeker T et al. Molecular and immunophenotypic characterization of AIDS-associated, Epstein - Barr negative, polyclonal lymphoma. J Clin Oncol 1992; 10: 383-388.
20. Cesarmen E, Chang Y, Moore PS, Said JW, Knowls DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-1191.
21. Hermine O, Michel M, Buzyn-Veil A. Body-cavity-based lymphoma in an HIV-serongative patient without Kaposi's sarcoma-associated herpesvirus-like DNA sequences. N Engl J Med 1996; 334: 272.
22. Nador RG, Cesarman E, Knowles DM, Said JW. Herpes-like DNA sequences in a body-cavity-based lymphoma in HIV-negative patient. N Engl J Med 1995; 333: 943.
23. Papadopoulous EB, Ladanyi M, Emanuel D et al. Infusion of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
24. Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. EBV induced polyclonal and monoclonal B-cell lymphoproliferative disease occuring after renal transplantation: clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 1983; 198: 356-369.
25. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorders after immunosuppression with monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723-1727.
26. Israel P. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767-1770.
27. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplant for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-787.
28. Frank D, Cesarman E, Liu YF, Michler RF, Knowels DM. Posttransplantation lymphoproliferative disorders frequently contain type A, and not type B Epstein-Barr virus. Blood 1995; 85: 1396-1403.
29. + phenotype. Cancer 1995; 75: 894-901.
30. Gutenshon N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 1981; 304: 135-140.
31. Weiss LM, Strickler JG, Warnke RA et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987; 129: 86-91.
32. Masih A, Wickert R, Mitchell D, Duggan M. The detection of EBV genome in Hodgkin's disease by dot-blot analysis and the polymerase chain reaction. Lab Invest 1990; 62: 64A(abstr).
33. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of EBV genome in Reed-Sternberg cells of HD. N Engl J Med 1989; 320: 502-506.
34. Pallesen G, Hamilton-Dutoit SJ, Rowe M et al. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 1991; 337: 320-322.
35. Schottenfeld D. Epidemiology of HD. In: Lacher MG, ed. Hodgkin's Disease. New York: Wiley, 1975: 5-20.
36. Gutensohn N, Cole P. Epidemiology of Hodgkin's disease. Int J Cancer 1977; 19: 595-601.
37. Tokudome S, Tokunaga O, Shimamoto Y, Miyamoto Y. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Saga, Japan. Cancer Res 1989; 49: 226-232.
38. Sakashita A, Hattori T, Miller CW. Mutation of the p53 gene in adult T-cell leukemia. Blood 1994; 79: 477-480.
39. Sadamori N, Kusano M, Nishino K. A translocation between chromosomes 8 and 14 in a Japanese patient with adult T-cell leukemia. Cancer Genet Cytogenet 1986; 20: 179-180.
40. Ramot B, Rechavi G. Primary intestinal lymphoma and alpha heavy chain disease. In: Magrath IT, ed. The Non-Hodgkin's Lymphomas. London: Edward Arnold, 1990: 352.
41. Pellet P, Berger R, Bernheim A. Molecular analysis of a t(9;14(p11 ; q32) translocation occurring in a case of human alpha heavy chain disease. Oncogene 1988; 4: 653-657.
42. Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-560.
43. Wotherspoon A, Doglion C, Diss TC. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-578.
44. Amariglio N, Rechavi G. Antibiotic responsive lymphoma: a case of bacterial superantigen? Leukemia Lymphoma (in press).
45. Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995; 267: 894-897.
46. Levine A. The tumor suppressor genes. Annu Rev Biochem 1993; 62: 623-651.
47. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
48. Pines J. Cell cycle: p21 inhibits cyclin shock. Nature 1994; 369: 520-521.
49. Kastan MB, Zhan Q, el-Deiry WS. A mammalian cell cycle check-point pathway utilizing p53 and GADD45 is defective in ataxia-telaniectasia. Cell 1992; 71: 587-597.
50. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Mgrath IT. The patterns of p53 mutations in Burkitt's lymphoma differ from those of solid tumors. Cancer Research 1992; 52: 4273-4276.
51. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10: 5502-5509.
52. Szekely L, Selivanova G, Magusson KP. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci 1993; 90: 5455-5459.
53. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-79.
54. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
55. Sarnow P, Ho YS, Williams J, Levine AJ, Adenovirus EIb, 58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982; 28: 387-394.
56. Williams GT. Programmed cell death: apoptosis and oncogenes. Cell 1991; 65: 1097-1098.
57. Pearson GR, Luka J, Petti L et al. Identification of an Epstein-Barr virus early gene encoding a second company of the restricted early antigen complex. Virology 1987; 160: 151-161.
58. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2 protects human B-cells from programmed cell death. PNAS 1993; 90: 8479-8483.
59. Neilan JG, Lu Z, Afonso CL, Kutish GF, Sussman MD, Rock DL. An African Swine Fever virus gene with similarity to the proto-oncogene bcl-2 and the Epstein-Barr virus gene BHRF1. J Virol 1993; 7: 4391-4394.
60. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-554.
61. Thanagavelu M, Olopade O, Beckman E. Clinical morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18) q32;q21) and t(g;14) (q24;q32) or t(8;22) (q24;q11). Genes, Chromosomes and Cancer 1990; 2: 147-158.
62. Lechner MS, Laminis LA. Variations in inhibition of p53 DNA binding by E6 proteins of different HPV types. J Virol 1994; 68: 4262-4273.
63. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein-Barr virus encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci 1993; 90: 5455-5459.